# Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

> **NCT05172518** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 512 (estimated)

## Conditions studied

- Breast Neoplasms
- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Taxane plus Intermittent Capecitabine
- **DRUG:** Utidelone plus Intermittent Capecitabine
- **DRUG:** Taxane plus Metronomic Capecitabine
- **DRUG:** Utidelone plus Metronomic Capecitabine

## Key facts

- **NCT ID:** NCT05172518
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 512 (ESTIMATED)
- **Last updated:** 2021-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172518, "Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05172518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*